With a market capitalization (market cap) of $1B — a measure of how much the company is worth — PROCEPT BioRobotics Corporation ranks #2,502 among the 2,502 companies tracked, and 353rd in Healthcare as of October 17, 2026. Shares trade at $17.57, down 3.20% on the day.
of 2,502 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 16, 2026. Ranking headline cap is the snapshot figure as of October 17, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 16, 2026 | $992.9M | -44.15% | $17.57 |
| 2025 | Dec 31, 2025 | $1.78B | -59.79% | $31.46 |
| 2024 | Dec 31, 2024 | $4.42B | +108.56% | $80.52 |
| 2023 | Dec 29, 2023 | $2.12B | +14.00% | $41.91 |
Ranking figure $1B as of October 17, 2026.
PROCEPT BioRobotics Corporation's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $17.57 as of October 16, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $992.9M on October 16, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 55,544,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.18T | +0.43% |
| #21 | Johnson & Johnson JNJ | $615.87B | +0.90% |
| #23 |
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH).
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 17, 2026, PROCEPT BioRobotics Corporation (PRCT) is worth $1B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, PROCEPT BioRobotics Corporation’s book equity is about $365.87M. Market cap is the market value of the outstanding shares. As of October 17, 2026, its market cap is $1B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
PROCEPT BioRobotics Corporation ranks #2,502 among the 2,502 companies tracked on MarketCapLens. In Healthcare it ranks #353 of 353.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
| 2022 |
|---|
| Dec 30, 2022 |
| $1.86B |
| +69.56% |
| $41.54 |
| 2021 | Dec 31, 2021 | $1.1B | — | $25.01 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $504.37B |
| +0.71% |
| #32 | UnitedHealth Group Incorporated UNH | $360.32B | -1.29% |
| #33 | Merck & Co., Inc. MRK | $360.12B | +0.53% |
| #45 | Novartis AG NVS | $286.29B | +0.16% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2499 | Hornbeck Offshore Services, Inc. HOS | $1.01B | +1.93% |
| #2500 | Capitol Federal Financial, Inc. CFFN | $1.01B | -0.79% |
| #2501 | Immatics N.V. IMTX | $1.01B | -5.74% |
PROCEPT BioRobotics Corporation’s ranking market cap of $1B comes from the same snapshot as the rest of this site, as of October 17, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 55,544,000. The historical market-cap series last observed $992.9M on October 16, 2026.
Over the past year, PROCEPT BioRobotics Corporation’s market cap is down 47.83%, using historical market-cap records rather than today’s share count applied to past prices.
PROCEPT BioRobotics Corporation (PRCT) shares trade at $17.57, down 3.20% on the day, as of October 17, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.